National Health (Listed drugs on F1 or F2) Amendment Determination 2015 (No. 7) (PB 82 of 2015) (Cth)

PB 82 of 2015

National Health (Listed drugs on F1 or F2) Amendment Determination 2015 (No. 7)

National Health Act 1953

I, ADRIANA PLATONA, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated           27       August 2015

ADRIANA PLATONA

Assistant Secretary

Pharmaceutical Evaluation Branch

Pharmaceutical Benefits Division

Department of Health

Part 1         Preliminary

1. Name of Determination

(1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2015 (No. 7).

(2)   This Determination may also be cited as PB 82 of 2015.

1. Commencement

This Determination commences on 1 September 2015.

1. Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).

Schedule 1             Amendments

(Section 3)

[1]     Schedule 1, after item dealing with Balsalazide

Omit

Bacillus Calmette and Guerin Connaught strain

Insert

Bacillus Calmette and Guerin, Connaught strain

[2]     Schedule 1, after item dealing with Clonidine

Omit

Clostridium botulinum toxin type A toxin-haemagglutinin complex

Insert

Clostridium Botulinum Type A Toxin-haemagglutinin Complex

[3]     Schedule 1, after item dealing with Crizotinib

Omit

Cyclephosphamide

Insert

Cyclophosphamide

[4]     Schedule 1, after item dealing with Ezetimibe

Insert

Febuxostat

[5]     Schedule 1, after item dealing with Fluorometholone

Omit

Flupenazine decanoate

Flupenthixol decanoate

Flurbiprofen

Insert

Flupenthixol Decanoate

Fluphenazine Decanoate

[6]     Schedule 1, after item dealing with Liothyronine

Insert

Lisdexamfetamine

[7]     Schedule 1, after item dealing with Lithium

Insert

Lutropin alfa

[8]     Schedule 1, after item dealing with Methylnaltrexone

Omit

Mexiletine

[9]     Schedule 1, after item dealing with Peginterferon Beta-1a

Insert

Pembrolizumab

[10]   Schedule 1, after item dealing with Saxagliptin

Insert

Secukinumab

[11]   Schedule 1, after item dealing with Tapentadol

Omit

Telaprevir

[12]   Schedule 2, after item dealing with Labetalol

Omit

Lactulose